Seong-Joon Kim

Seong-Joon Kim

Auto-generated profile, based on publicly available information

Seong-Joon Kim

Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Ophthalmology
Verified
Journal Article
Open access
AHAhnul Ha
Ahnul Ha
SKSeong Joon Kim
Seong Joon Kim
SSSung Ryul Shim
Sung Ryul Shim
YKYoung-Kook Kim
Young-Kook Kim
Jae Ho JungJae Ho Jung
Jae Ho Jung
Comparative efficacy and safety of different concentrations of atropine for myopia control. Atropine is known to be an effective intervention to delay myopia progression. Nonetheless, no well-supported evidence exists yet to rank the clinical outcomes of various concentrations of atropine. We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov on April 14, 2021. We selected studies involving atropine treatment of at least 1 year's duration for myopia control in children. We performed a network meta-analysis (NMA) of randomized controlled trials (RCTs) and compared 8 atropine concentrations (1% to 0.01%). We ranked the atropine concentrations for the corresponding outcomes by P score (estimate of probability of being best treatment). Our primary outcomes were mean annual changes in refraction (diopters/year) and axial length (AXL; millimeters/year). We extracted data on the proportion of eyes showing myopia progression and safety outcomes (photopic and mesopic pupil diameter, accommodation amplitude, and distance and near best-corrected visual acuity [BCVA]). Thirty pairwise comparisons from 16 RCTs (3272 participants) were obtained. Our NMA ranked the 1%, 0.5%, and 0.05% atropine concentrations as the 3 most beneficial for myopia control, as assessed for both primary outcomes: 1% atropine (mean differences compared with control: refraction, 0.81 [95% confidence interval (CI), 0.58-1.04]; AXL, -0.35 [-0.46 to -0.25]); 0.5% atropine (mean differences compared with control: refraction, 0.70 [95% CI, 0.40-1.00]; AXL, -0.23 [-0.38 to -0.07]); 0.05% atropine (mean differences compared with control: refraction, 0.62 [95% CI, 0.17-1.07]; AXL, -0.25 [-0.44 to -0.06]). In terms of myopia control as assessed by relative risk (RR) for overall myopia progression, 0.05% was ranked as the most beneficial concentration (RR, 0.39 [95% CI, 0.27-0.57]). The risk for adverse effects tended to rise as the atropine concentration was increased, although this tendency was not evident for distance BCVA. No valid network was formed for near BCVA. The ranking probability for efficacy was not proportional to dose (i.e., 0.05% atropine was comparable with that of high-dose atropine [1% and 0.5%]), although those for pupil size and accommodation amplitude were dose related.

1 December 2008 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Closed access
ELEun Ji Lee
Eun Ji Lee
SKSeong-Joon Kim
Seong-Joon Kim
HCHo Kyung Choung
Ho Kyung Choung
JKJeong Hun Kim
Jeong Hun Kim
YYYoung Suk Yu
Young Suk Yu
Background: The incidence, clinical manifestations, and contributory factors in ethambutol-induced optic neuropathy (EON) have not been widely studied. Methods: A retrospective chart review of 857 patients who took ethambutol for treatment of tuberculosis identified 89 patients who complained of decreased vision after initiation of treatment and were therefore referred to the ophthalmology clinic of Seoul National University Hospital, Korea, between January 2003 and December 2005. Information was extracted in regard to systemic illnesses, duration and dose of ethambutol therapy, visual acuity, color vision, ophthalmoscopic examination, visual fields, and visual evoked potentials (VEPs). Results: EON was diagnosed in 13 (1.5%) patients during a follow-up period of 12.54 ± 9.97 months. The average dose of ethambutol was 17.85 ± 2.21 mg/kg/day, and the duration of therapy was 9.38 ± 10.12 months. Ophthalmic findings included decreased visual acuity (65.4%), abnormal visual fields (65.4%), abnormal color vision (61.5%), optic disc pallor (38.5%), or increased latency on VEP tests (65.4%). Slightly less than one third of patients showed improvement in visual function after discontinuing ethambutol. The latency for recovery was 5.38 ± 1.71 months. No patient with optic disc pallor at the time of diagnosis of EON showed visual function improvement. Renal dysfunction and the daily dose of ethambutol, but not the duration of treatment, contributed to EON. Conclusions: Based on this study, the incidence of EON in Koreans is estimated to be <2%. However, visual function after discontinuation of ethambutol is reversible in only a minority of patients and does not occur if optic disc pallor is present. Renal dysfunction and daily dose of ethambutol, but not duration of ethambutol treatment, seem to be related to development of EON.

31 October 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
HLHaeng Jin Lee
Haeng Jin Lee
BKBoram Kim
Boram Kim
PWPatrick Waters
Patrick Waters
MWMark Woodhall
Mark Woodhall
SISarosh R Irani
Sarosh R Irani
SKSung-Min Kim
Sung-Min Kim
Key clinical features of chronic relapsing inflammatory optic neuropathy (CRION) include relapsing inflammatory optic neuritis (ON) and steroid dependency, both of which have been reported among patients with myelin oligodendrocyte glycoprotein antibodies (MOG-Abs). We investigated the relevance of the presence of serum MOG-IgG with the current diagnostic criteria for CRION among patients with idiopathic inflammatory optic neuritis (iON). Retrospective reviews of a database prospectively collated between 2011 and 2017 from the tertiary referral center for multiple sclerosis and neuromyelitis optica were performed. Sixty-four patients with iON, who did not meet the diagnostic criteria for multiple sclerosis, neuromyelitis optica (NMO) spectrum disorder with/without NMO-IgG, or acute disseminated encephalomyelitis and who had no symptomatic central nervous system (CNS) lesions other than on the optic nerve, were included from a cohort of 615 patients with inflammatory demyelinating diseases of the CNS. Fulfillment of the current diagnostic criteria for CRION, assay results for the serum IgG1 MOG-Ab, and characteristics of CRION patients with MOG-IgG were compared to those of non-CRION patients with MOG-IgG. Twelve iON patients fulfilled the current diagnostic criteria for CRION, 11 patients were positive for MOG-IgG, and one patient was borderline. Among the other 52 iON patients not meeting the criteria for CRION, 14 had relapsing disease courses and 38 had monophasic courses, of which MOG-IgG positivity were 0% and 29%, respectively. CRION patients with MOG-IgG had more relapsing disease courses (first steroid-dependent worsening/relapse in 2.3 months, range 0.4–7.0) and poorer optical coherence tomography outcomes at follow-up than non-CRION patients with MOG-IgG. However, patients in the two groups did not differ in terms of age of onset, sex, or steroid treatment duration after initial attack. CRION, according to the current diagnostic criteria, is a relapsing optic neuritis associated with MOG-IgG. Among iON patients with MOG-IgG, the absence of steroid-dependent attacks in the early stages of the disease may predict a long-term non-relapsing disease course and a more favorable outcome.

28 October 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
YKYoung Nam Kwon
Young Nam Kwon
BKBoram Kim
Boram Kim
JKJun-Soon Kim
Jun-Soon Kim
HMHeejung Mo
Heejung Mo
KCKyomin Choi
Kyomin Choi
SKSung-Min Kim
Sung-Min Kim
Background and Objective To investigate the clinical relevance of CSF myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) testing in a large multicenter cohort. Methods In this multicenter cohort study, paired serum-CSF samples from 474 patients with suspected inflammatory demyelinating disease (IDD) from 11 referral hospitals were included. After serum screening, patients were grouped into seropositive myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD, 31), aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD, 60), other IDDs (217), multiple sclerosis (MS, 45), and non-IDDs (121). We then screened CSF for MOG-IgG and compared the clinical and serologic characteristics of patients uniquely positive for MOG-IgG in the CSF to seropositive patients with MOGAD. Results Nineteen patients with seropositive MOGAD (61.3%), 9 with other IDDs (CSF MOG + IDD, 4.1%), 4 with MS (8.9%), but none with AQP4-IgG + NMOSD nor with non-IDDs tested positive in the CSF for MOG-IgG. The clinical, pathologic, and prognostic features of patients uniquely positive for CSF MOG-IgG, with a non-MS phenotype, were comparable with those of seropositive MOGAD. Intrathecal MOG-IgG synthesis, observed from the onset of disease, was shown in 12 patients: 4 of 28 who were seropositive and 8 who were uniquely CSF positive, all of whom had involvement of either brain or spinal cord. Both CSF MOG-IgG titer and corrected CSF/serum MOG-IgG index, but not serum MOG-IgG titer, were associated with disability, CSF pleocytosis, and level of CSF proteins. Discussion CSF MOG-IgG is found in IDD other than MS and also in MS. In IDD other than MS, the CSF MOG-IgG positivity can support the diagnosis of MOGAD. The synthesis of MOG-IgG in the CNS of patients with MOGAD can be detected from the onset of the disease and is associated with the severity of the disease. Classification of Evidence This study provides Class II evidence that the presence of CSF MOG-IgG can improve the diagnosis of MOGAD in the absence of an MS phenotype, and intrathecal synthesis of MOG-IgG was associated with increased disability.

23 September 2019 in Japanese Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
HLHaeng-Jin Lee
Haeng-Jin Lee
SKSeong-Joon Kim
Seong-Joon Kim

22 October 2013 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
YKYong Woo Kim
Yong Woo Kim
SKSeong-Joon Kim
Seong-Joon Kim
YYYoung Suk Yu
Young Suk Yu